Skip Navigation

European Heart Journal 1999 20(21):1538-1552; doi:10.1053/euhj.1999.1850
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pratt, C.M
Right arrow Articles by Waldo, A.L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pratt, C.M
Right arrow Articles by Waldo, A.L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?

C.M Pratta,f1, A.J Cammb, J.T Bigger, Jrc, G Breithardtd, R.W.F Campbelle,f2, A.E Epsteinf, L.J Kappenbergerg, K.-H Kuckh, S Pococki, S Saksenaj and A.L Waldok

a Baylor College of Medicine, Houston, U.S.A.
b St. George's Hospital Medical School, London, U.K.
c Columbia University, New York, U.S.A.
d Westfälische-Wilhelms Universität, Münster, Germany
e Freeman Hospital, Newcastle upon Tyne, U.K.
f University of Alabama, Birmingham, U.S.A.
g CHUV, Lausanne, Switzerland
h St. Georg Krankenhauses, Hamburg, Germany
i London School of Hygiene & Tropical Medicine, London, U.K.
j Eastern Institute General Hospital, Passaic, U.S.A.
k Case Western Reserve University, Cleveland, U.S.A.

revised June 29, 1999; accepted July 7, 1999

Abstract

A report from a Study group, proposed by A. J. Camm, London, of the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology; co-sponsored by the North American Society of Pacing and Electrophysiology. The Study Group was convened on 29 August 1997 at Saltsjöbaden, near Stockholm. The meeting was chaired by A. J. Camm, London, and C. M. Pratt, Houston. Based on the presentation and discussions, a first draft of the documents was prepared by C. Pratt and J. Camm which was then circulated to all members three times for their review. All members of the Study Group approved the final manuscript. This report represents the opinion of the members of this Study Group and does not necessarily reflect the official position of either society.

The meeting of the Study Group was made possible by unrestricted educational grants from Medtronic, Guidant, Proctor & Gamble, Berlex and Sanofi.

Also, presented, in part, at the Cardio-Renal Drugs Advisory Board meeting of the Food and Drug Administration, Bethesda, Maryland, on 30 April 1999.

f1 Correspondence: Dr Craig Pratt, Professor of Medicine, Department of Internal Medicine, Section of Cardiology, Baylor College of Medicine, 6565 Fannin, M.S. F-1001, Houston, Texas 77030, U.S.A.

f2 This paper is dedicated to the memory of Ronald W. F. Campbell (Ronnie) whose enthusiasm for and insight into clinical cardiology research is truly missed.

References

  1. Siebels J, Cappato R, Ruppel R. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol. 1993;72:109F–113F[CrossRef][Medline]
  2. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994;127:1139–1144[CrossRef][Web of Science][Medline]
  3. N Engl J Med. 1997;337:1576–1583[Abstract/Free Full Text]
  4. Moss AJ, Hall J, Cannom DS. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med. 1996;335:1933–1940[Abstract/Free Full Text]
  5. Hohnloser SH, Singh BN. Proarrhythmia with Class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol. 1995;6:920–936[Web of Science][Medline]
  6. Sagie A, Strasberg B, Kusniec J. Rapid suppression of flecainide induced incessant ventricular tachycardia with high dose intravenous amiodarone. Chest. 1988;93:879–880[Abstract/Free Full Text]
  7. Gottlieb CD, Horowitz LN. Potential interactions between antiarrhythmic medication and the automatic implantable cardioverter defibrillator. PACE. 1991;14:898–904
  8. Echt DS, Gremillion ST, Lee JT. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol. 1994;5:752–760[Web of Science][Medline]
  9. N Engl J Med. 1989;321:406–412[Abstract]
  10. N Engl J Med. 1992;327:227–233[Abstract]
  11. Waldo AL, Camm AJ, de Ruyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after myocardial infarction. Lancet. 1996;348:7–12[CrossRef][Web of Science][Medline]
  12. Pratt CM, Camm AJ, Cooper W. Mortality in the survival with oral d-sotalol (SWORD) trial. Why did patients die? Am J Cardiol. 1998;81:869–876[CrossRef][Web of Science][Medline]
  13. Julian DG, Camm AJ, Frangin G. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667–674[CrossRef][Web of Science][Medline]
  14. Janse MJ, Malik M, Camm AJ. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J. 1998;19:85–95[Abstract/Free Full Text]
  15. Clin Cardiol. 1997;20:704–710[Web of Science][Medline]
  16. J Am Coll Cardiol. 1999;33:132A
  17. Connolly SJ, Gent M, Roberts RS. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol. 1993;72:103F–108F[CrossRef][Medline]
  18. Bigger JT. Prophylactic use of implantable cardioverter defibrillators in patients at risk of ventricular arrhythmias after coronary artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) patch trial investigators. N Engl J Med. 1997;337:1569–1575[Abstract/Free Full Text]
  19. Buxton AE, Lee KL, DeCarlo L. Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained ventricular tachycardia. MUSTT Investigators. Ann Intern Med. 1996;125:35–39[Abstract/Free Full Text]
  20. Bardy GH, Lee KL, Mark DB. The Sudden Cardiac Death in Heart Failure Trial: pilot study (Abstr). PACE. 1997;20:1148
  21. Moss AJ, Connom DS, Dubert JP. Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): design and clinical protocol. Ann Noninvasiv Electrocardiol. 1999;4:83–91
  22. Nisam S, Mower M. ICD trials: an extraordinary means of determining patient risk? PACE. 1998;21:1341–1346
  23. Hinkle LE, Thaler HT. Clinical classification of cardiac deaths. Circulation. 1982;65:457–464[Abstract/Free Full Text]
  24. Kim SG, Fogoros RN, Furman S. Standardized reporting of ICD patient outcome: the report of a North American Society of Pacing & Electrophysiology Policy Conference, February 9–10, 1993. Pacing Clin Electrophysiol. 1993;16:1358–1362[CrossRef][Medline]
  25. Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol. 1993;72:70F–74F[CrossRef][Medline]
  26. Dolack GL. Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation. Am J Cardiol. 1994;73:237–241[CrossRef][Web of Science][Medline]
  27. Am J Cardiol. 1993;72:280–287[CrossRef][Web of Science][Medline]
  28. Böcker D, Block M, Isbruch F. Comparison of frequency of aggravation of ventricular tachyarrythmias after implantation of automatic defibrillators using epicardial versus nonthoractomy lead systems. Am J Cardiol. 1993;71:1064–1068[CrossRef][Web of Science][Medline]
  29. Echt DS, Leibson PR, Mitchell B. Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med. 1991;324:781–788[Abstract]
  30. Grimm W, Flores BF, Marchilinski FE. Symptoms and electrocardiographically documented rhythm preceding spontaneous shocks in patients with implantable cardioverter defibrillator. Am J Cardiol. 1993;71:1415–1418[CrossRef][Web of Science][Medline]
  31. Hook BG, Callans DJ, Kleiman RB. Implantable cardioverter defibrillator therapy in the absence of significant symptoms: Rhythm diagnosis and management aided by stored electrogram analysis. Circulation. 1993;87:1897–1906[Abstract/Free Full Text]
  32. Kou WH, Calkins H, Lewis RR. Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Intern Med. 1991;115:942–945[Abstract/Free Full Text]
  33. Bansch D, Brunn J, Castrucci M. Syncope in patients with an implantable cardioverter defibrillator incidence, prediction and implications for driving restrictions. J Am Coll Cardiol. 1998;31:608–615[Abstract/Free Full Text]
  34. Wietholt D, Block M, Isbruch F. Clinical experience with antitachycardia pacing and improved detection algorithms in a new implantable cardioverter defibrillator. J Am Coll Cardiol. 1993;21:885–894[Abstract]
  35. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989;117:151–159[CrossRef][Web of Science][Medline]
  36. Exner DV, Gillis AM, Sheldon RS. Telemetry documented, pace terminable ventricular tachycardia in patients with ventricular fibrillation. Am J Cardiol. 1998;81:235–238[CrossRef][Web of Science][Medline]
  37. Böcker D, Block M, Isbruch F. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol. 1993;21:1638–1644[Abstract]
  38. Böcker D, Bansch D, Henecke A. Potential benefit from implantable cardioverter defibrillator therapy in patients with and without heart failure. Circulation. 1998;98:1636–1643[Abstract/Free Full Text]
  39. Stevens SK, Haffajee CI, Naccarelli GV. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter defibrillators. J Am Coll Cardiol. 1996;28:418–422[Abstract]
  40. Jung W, Manz M, Pizzulli L. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992;70:1023–1027[CrossRef][Web of Science][Medline]
  41. Movsowitz C, Marchlinksi FE. Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol. 1998;82:411–481
  42. Tacker WA, Niebauer MJ, Babbs CF. The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med. 1980;8:177–180[Web of Science][Medline]
  43. Wang M, Dorian P. dL and d-sotalol decrease defibrillation energy requirements. PACE. 1989;12:1522–1529
  44. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol. 1993;72:72A–79A[CrossRef][Medline]
  45. Jung W, Manz M, Pizzulli L. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992;70:1023–1027[CrossRef][Web of Science][Medline]
  46. Gilberg JM, Olson WH, Bardy GH. Electrogram width algorithm for discrimination of supraventricular rhythm from ventricular tachycardia (Abstr). PACE. 1994;17:866
  47. Ruetz LL, Bardy GH, Mitchell LB. Clinical evaluation of electrogram width measurements for automatic ventricular tachycardia (Abstr). PACE. 1996;19:582
  48. Osswald S, Cron TA, Sterns L. New ICD technologies: first clinical experience with dual chamber sensing for differentiation of supraventricular arrhythmias. PACE. 1998;21:292–295
  49. Bardy GH, Olson W, Barnes J. Ventricular fibrillation cycle length spectrum: measured values in comparison to sensed values as a function of ICD sensitivity setting (Abstr). PACE. 1993;16:585
  50. Bardy GH, Ivey T, Stewart R. Failure of the automatic implantable cardioverter defibrillator to detect ventricular fibrillation. Am J Cardiol. 1986;58:1107–1108[CrossRef][Web of Science][Medline]
  51. Cohen TJ, Liem LB. Biosensor applications to antitachycardia devices. PACE. 1991;14:322–328
  52. Prevot E, Vesin JM, Schmidiager H. Analysis of heart rate variability at the onset of spontaneous ventricular tachyarrhythmias as retrieved from a defibrillator. Eur Heart J. 1977;18:592
  53. Vetter R, Celka P, Vesin JM. Subband modeling of the human cardiovascular system: new insights into cardiovascular regulation. Ann Biomed Eng. 1998;26:293–307[CrossRef][Web of Science][Medline]
  54. Cohen TJ, Liem LB. A hemodynamically responsive antitachycardia system. Development and basis for design in humans. Circulation. 1990;82:394–406[Abstract/Free Full Text]
  55. Kaye GC, Astridge P, Perrins J. Tachycardia recognition and diagnosis from changes in right atrial pressure waveform—a feasibility study. PACE. 1991;14:1384–1392
  56. Wood MA, Ellenbogen KA, Kapadia K. Comparison of right ventricular emepdance, pulse pressure and maximal dP/dt for determination of hemodynamic stability of ventricular arrhythmias associated with coronary artery disease. Am J Cardiol. 1990;66:575–582[CrossRef][Web of Science][Medline]
  57. Krahn AD, Klein GJ, Norris C. The etiology of syncope in patients with negative tilt table and electrophysiological testing. Circulation. 1995;92:1819–1824[Abstract/Free Full Text]
  58. Pratt CM, Greenway PS, Schoenfeld MH. An exploration of th precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials. Circulation. 1996;93:519–524[Abstract/Free Full Text]
  59. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective. Con Clin Trials. 1997;18:530–545
  60. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics. 1987;43:487–498[CrossRef][Web of Science][Medline]
  61. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079–1087[CrossRef][Web of Science][Medline]
  62. Raviele A, Bongiorni MG, Brignole M. Which strategy is ‘best’ after myocardial infarction? The Beta-blocker Strategy Plus Implantable Cardioverter Defibrillator Trial: rationale and study design. Am J Cardiol. 1999;83:104D–111D[CrossRef][Web of Science][Medline]
  63. Wever EFD, Hauer RNW, van Capelle FJI. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in post-infarct study death survivors. Circulation. 1995;91:2195–2203[Abstract/Free Full Text]
  64. Myerburg RJ, Luceri RM, Thurer R. Time to first shock and clinical outcome in patients receiving an implantable cardioverter-defibrillator. J Am Coll Cardiol. 1989;4:508–514
  65. Huang SKS, Tan de Guzman WLT, Chenarides JG. Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J. 1991;122:720–727[CrossRef][Web of Science][Medline]
  66. Grimm W, Flores BT, Marchlinski FE. Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation. 1993;7:1880–1888
  67. Kelly PA, Cannom DS, Garan H. The automatic implantable cardioverter defibrillator: efficacy, complications and survival in patients with malignant ventricular arrhythmias. J Am Coll Cardiol. 1998;11:1278–1286
  68. Saksena S, Poczobutt-Johanos M, Castle LW. Long-term multicenter experience with a second-generation implantable pacemaker-defibrillator in patients with malignant ventricular tachyarrhythmias. The Guardian Multicenter Investigators Group. J Am Coll Cardiol. 1992;19:490–499[Abstract]
  69. Echt DS, Armstrong K, Schmidt P. Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter-defibrillator. Circulation. 1985;71:289–296[Abstract/Free Full Text]
  70. Pacifico A, Hohnloser SH, Williams JH. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Eng J Med. 1999;340:1855–1862[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
G. Boriani, A. Lubinski, A. Capucci, P. Niederle, Z. Kornacewicz-Jack, A.M. Wnuk-Wojnar, M. Borggrefe, J. Brachmann, M. Biffi, G.S. Butrous, et al.
A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease
Eur. Heart J., December 1, 2001; 22(23): 2180 - 2191.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
J. P. DiMarco
Is programmed stimulation in survivors of myocardial infarction helpful?
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1908 - 1909.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pratt, C.M
Right arrow Articles by Waldo, A.L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pratt, C.M
Right arrow Articles by Waldo, A.L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?